Download Library
Document Type
View Press Release
Fixed dose combination of AR-13324 and latanoprost (PG324): A double-masked, randomized, controlled study in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)
Presentations
View Presentation
View Transcript
View Presentation
Selective Multi-kinase Inhibitor of ROCK/JAK/PDGFR-B; Reduces Laser-induced CNV in Rats
Presentations
Effects of Rho kinase inhibitor AR-13324 on actin cytoskeleton and TGFB2- and CTGF-induced fibrogenic activity in Human Trabecular Meshwork Cells
Presentations
Effect of AR-13324 on episcleral venous pressure (EVP) in Dutch Belted rabbits (Presented at Association for Research in Vision and Ophthalmology, 2014)
Presentations
Double-masked, randomized, dose-response study of AR-13324 Ophthalmic Solution compared to latanoprost in patients with elevated intraocular pressure (Presented at American Glaucoma Society, 2014)
Presentations
Code of Business Conduct and Ethics
Page: FirstPrevious
3
NextLast
= add file to Briefcase